Stomach cancer (also called gastric cancer) begins when cells in the stomach grow out of control and take over healthy cells. The cancer may grow along the stomach wall into the esophagus or small intestine.
Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor
Stomach Cancer :: Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ?) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.The data monitoring committee overseeing the trial (known as ACOSOG Z9001*) recommended that the results from a recent interim analysis be made public because the study had met is primary endpoint of increasing recurrence-free survival.
"The standard treatment for primary GIST is complete surgical removal of the tumor without additional therapy," said Elias A. Zerhouni, M.D., NIH Director. "It is excellent news that addition of this well-tolerated cancer pill to the treatment regimen can have such a positive impact on decreasing the risk of recurrence."
Researchers found that approximately 97 per cent of patients in the study who received one year of imatinib after surgery did not have a recurrence of their cancer compared to 83 percent of patients who received one year of placebo. In addition, imatinib therapy was well tolerated by most patients enrolled in the study. The types of side effects observed in this trial were similar to those observed in other clinical trials with imatinib, and included nausea, diarrhea, and swelling. Presentation of detailed results from this trial is planned for a future scientific meeting.
"These results have major implications for patients with primary GIST," noted the principal investigator of the study, Ronald DeMatteo, M.D., Memorial Sloan-Kettering Cancer Center, New York, N.Y. "Conventional chemotherapy agents have been notoriously ineffective in GIST. This study for the first time demonstrated that targeted molecular therapy reduces the rate of recurrence after complete removal of a primary GIST."
Information on over 600 patients enrolled on this study was used in the analysis. Patients participated through one of five NCI-sponsored North American Cooperative Oncology Groups, led by ACOSOG and including Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, Southwest Oncology Group, and the National Cancer Institute of Canada, Clinical Trials Group.
Patients with primary tumors three centimeters or larger that had been completely removed with surgery were enrolled in the trial between June 2002 and April 2007. Patients were randomized to one of two treatment arms. One patient group received imatinib at a dose of 400 milligrams per day for one year. The second group received placebo for one year. Neither the patients nor their physicians knew which treatment the patients were receiving. Patients who developed a recurrence of their cancer while on study therapy were unblinded to their treatment assignment. Those patients who had been on placebo subsequently received imatinib and those who had been on imatinib continued their imatinib therapy, but at a higher dose. There was no difference in overall survival for patients on the two treatment arms.
(Stomach Cancer :: Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor published at SpiritIndia on Saturday, April 14, 2007)
Stomach Cancer
Search more information on Stomach Cancer, Stomach Cancer booksRecently posted related articles on Stomach Cancer :
- Stomach Cancer :: Stem cell discovery could aid search for how stomach cancer begins
- Stomach Cancer :: Stomach cancer rate set to fall further 25 percent over next decade
- Stomach Cancer :: Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor
- Stomach Cancer :: Roche's Xeloda in Europe for stomach cancer
- Stomach Cancer :: Simple 2-gene test sorts out similar gastrointestinal cancers
- Stomach Cancer :: Napoleon's mysterious death unmasked
- Stomach Cancer :: Scientists reverse precursor to gut cancer
- Stomach Cancer :: Family size influences the stomach cancer risk
- Stomach Cancer :: Helicobacter pylori and stomach cancer
- Stomach Cancer :: Removal of lymphnodes boost survival of stomach cancer patient
Most related articles:
- Stomach Cancer :: Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor- Cancer :: OHSU Cancer Institute, 1 of largest in GIST study and Gleevec - 18.6
- Stomach Cancer :: Simple 2-gene test sorts out similar gastrointestinal cancers - 12.3
- Tumor :: A little more PDGF-BB, a little less tumor growth - 12.1
- Cancer :: Sutent, sunitinib for Gastrointestinal - Stomach Cancer, Kidney Cancer - 11.6
- Prostate Cancer :: A new test may determine the recurrence of prostate cancer - 11.5
- Kidney Cancer :: B.C. first to fund new drug therapies for kidney cancer - 10.9
- Stem Cell :: Linheng Li Lab documents the development of cancer stem cells - 10.6
- Ovarian Cancer :: Clumping protein linked to return of ovarian cancer - 10.1
- Esophageal Cancer :: Dua anti-reflux stent relieves GI upper cancer distress - 9.6
»» Obesity :: Sporting research aims to reduce childhood obesity
«« Medicare :: AARP applauds Senate Finance Committee for Passing Medicare Rx Bargaining Bill
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com